Histological, immunological and molecular features of a nasal mucosa primary melanoma associated with nasal melanosis by Hofbauer, G F L et al.








Histological, immunological and molecular features of a nasal mucosa
primary melanoma associated with nasal melanosis
Hofbauer, G F L; Böni, R; Simmen, D; Mihic, D; Nestle, F O; Burg, G; Dummer, R
Abstract: Nasal mucosa melanoma is a rare entity that may occur together with nasal melanosis. The
histological and immunological features and loss of heterozygosity analysis of such lesions have not been
reported to date. In the study presented here short-term cell cultures were established from the patient’s
melanoma and subsequent relapses. Histology, immunohistochemistry, reverse transcription-polymerase
chain reaction enzyme-linked immunosorbent assay, human leukocyte antigen analysis, microdissection
with subsequent polymerase chain reaction for analysis of loss of heterozygosity were used to characterize
the tumour and other cells. Melanoma of the nasal cavity was found, with a surrounding proliferation
of atypical melanocytes corresponding to nasal melanosis. Immunoreactivity was found for S-100, gp100,
tyrosinase and MelanA protein. Loss of heterozygosity for a p16-flanking marker was found in the
tumour and the melanotic cells. Short-term cell cultures expressed tyrosinase and MUC18 at the mRNA
level and intercellular adhesion molecule-1 (ICAM-1) and interleukin-12 receptor at the protein level.
This is the first time short-term cell cultures have been established and analysed from such a tumour.
Melanoma-associated antigens were identified within the tumour. The melanoma and the melanotic cells
showed loss of heterozygosity for the p16 gene, which is implicated in melanoma development. This
points to a common origin in tumorigenesis. Pathways of tumour escape, such as expression of CD54
and interleukin-10, were observed. The clinical, immunological and molecular features suggest that nasal
melanosis should be followed closely.
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Nasal mucosa melanoma is a rare entity that may occur
together with nasal melanosis. The histological and immu-
nological features and loss of heterozygosity analysis of
such lesions have not been reported to date. In the study
presented here short-term cell cultures were established
from the patient's melanoma and subsequent relapses.
Histology, immunohistochemistry, reverse transcription-
polymerase chain reaction enzyme-linked immunosorbent
assay, human leukocyte antigen analysis, microdissection
with subsequent polymerase chain reaction for analysis of
loss of heterozygosity were used to characterize the
tumour and other cells. Melanoma of the nasal cavity was
found, with a surrounding proliferation of atypical melano-
cytes corresponding to nasal melanosis. Immunoreactivity
was found for S-100, gp100, tyrosinase and MelanA protein.
Loss of heterozygosity for a p16-¯anking marker was found
in the tumour and the melanotic cells. Short-term cell
cultures expressed tyrosinase and MUC18 at the mRNA
level and intercellular adhesion molecule-1 (ICAM-1) and
interleukin-12 receptor at the protein level. This is the ®rst
time short-term cell cultures have been established and
analysed from such a tumour. Melanoma-associated anti-
gens were identi®ed within the tumour. The melanoma and
the melanotic cells showed loss of heterozygosity for the
p16 gene, which is implicated in melanoma development.
This points to a common origin in tumorigenesis. Pathways
of tumour escape, such as expression of CD54 and
interleukin-10, were observed. The clinical, immunological
and molecular features suggest that nasal melanosis
should be followed closely. & 2002 Lippincott Williams &
Wilkins
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Introduction
Mucosal melanosis is a prominent hyperpigmenta-
tion of the basal layer that is accentuated at the tip
of the rete ridges.
1
Malignant melanoma of the nasal
cavity or paranasal sinus is a rare disorder.
2
Mucosal
melanosis of the nasal or paranasal mucosa in
association with melanoma is even more uncom-
mon. A relationship between nasal melanosis and
increased incidence of nasal and paranasal melano-
ma has been suggested in persons of African
descent
3
and has been documented in one patient.
4
We report a novel case of nasal melanoma in a
Caucasian patient with mucosal melanosis that was
analysed at the molecular level.
Case report
A 39-year-old white male presented to the Depart-
ments of Head and Neck Surgery and Dermatology
at our institution in June 1994. He had a 4-year
history of obstructed nose breathing, and com-
plained of a decreased sense of smell and occasional
epistaxis. In April 1994 he had noticed a nodule
growing in his left nostril. At the time of presenta-
tion, an endonasal endoscopic procedure with ante-
rior ethmoidectomy and conchotomy was
performed. The histological examination revealed
malignant melanoma with mucosal polyposis of the
paranasal sinuses.
Imaging studies, including positron emission to-
mography (PET),
5
were performed for staging pur-
poses: remaining tumour, with no metastases, was
detected (pTxN0M0). During an endonasal endo-
scopic revision of the residual tumour in the left
maxillary and anterior ethmoid sinuses, extensive
mucosal melanosis was discovered within the left
nasal cavity (see Figure 1).To whom correspondence should be addressed
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In November 1994 a `second-look' procedure was
performed, and a local recurrence and two foci of
melanosis were removed. Adjuvant percutaneous
radiation therapy (total dose of 54 Gy) was admin-
istered to the nose, ethmoid cavity and cervical
lymph nodes. In March 1995 a third local recurrence
was observed and was again endoscopically removed
by the Ear, Nose and Throat Department.
Interferon-á2b and interleukin-2 were given as
adjuvant therapy from April 1995 to March 1996.
6
In
September 1995 a fourth local recurrence of the
malignant melanoma was treated by revision of the
endonasal medial maxillectomy and a subtotal muco-
sa resection of the nasal septum on the left side. In
June 1996 suspicious alterations in lymph nodes
were noted on computed tomography (CT) and PET
Figure 1. (a) Mucosal melanosis of the left nasal septum as seen on endoscopy. Primary melanoma showing the melanosis at
periphery stained with hematoxylin-eosin. (b) and stained for S100. (c) gp100. (d) Tyrosinase. (e) and MelanA/MART-1. (f) (original
magni®cation 1003).
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scan. A left-sided modi®ed radical neck dissection
was performed in July 1996. Five of the 34 lymph
nodes removed were positive for metastasis. In
November 1996 imaging studies showed local and
regional recurrence. In December 1996 a cervical
lymphadenectomy yielded a positive lymph node
and the original tumour site was surgically revised.
An additional cervical lymphadenectomy was per-
formed in February 1997, yielding another positive
lymph node.
As a part of a clinical study, the patient received
dendritic cell vaccination with melanoma-associated
antigen peptides.
7
Six injections into the inguinal
lymph nodes with gp100-, tyrosinase- and MelanA/
MART-1-pulsed dendritic cells were performed be-
tween February 1997 and April 1997. The nasal
tumour mass decreased on imaging studies, but
metastases in the right upper pulmonary lobe, the
lingula and the pancreas were observed. In June
1997 another lymphadenectomy, a partial resection
of the nasal septum, and extended local revision and
resection of a satellite metastasis of the left cheek
were performed.
In June 1997 a recombinant canary-pox virus
transduced with granulocyte/macrophage colony
stimulating factor (GMCSF) was applied to a sub-
cutaneous metastasis on the left neck as part of a
phase I clinical trial. Imaging studies in July 1997
showed progression of pulmonary and abdominal
metastases and new metastases to the liver and
adrenal glands. Palliative chemoimmunotherapy
using dacarbazine, cisplatin, interferon-á and inter-
leukin-2 was initiated in July 1997.
8
The patient
received six treatment cycles. Dosage was adjusted
to minimize side-effects, which included nausea,
emesis, diarrhoea, fatigue, erosive oral ulcerations
and acute renal insuf®ciency with oliguria. The
dosage of interferon-á was reduced due to recurring
leukopenia. After the last cycle of chemoimmuno-
therapy in January 1998, imaging studies demon-
strated further progressive disease in the maxillary
sinus, chest and abdomen, but no new lesions were
noted.
In March 1998 the patient developed progressive
visual loss and headache. Multiple cerebral meta-
stases, as well as progression of the previously
known metastases, were detected on imaging stud-
ies. Additionally, the patient suffered a pathological
fracture of the right upper arm, which was treated
surgically. Systemic steroids were given, and radio-
therapy with a total dose of 20 Gy was administered
to the brain. The cerebral symptoms improved
slightly. In June 1998 the patient succumbed to his
disease.
Methods
Formalin-®xed paraf®n-embedded tissue was used
for routine histology and for immunohistochemistry
using monoclonal antibodies and the alkaline phos-
phatase±anti-alkaline phosphatase method.
9±11
Total RNA from short-term melanoma cell cultures
established from two lymph node metastases were
analysed by reverse transcription-polymerase chain
reaction enzyme-linked immunosorbent assay (RT-
PCR ELISA) for tyrosinase, MUC18, MAGE-3 and
MelanA/MART-1 mRNA expression.
12
The human leukocyte antigen (HLA) status of
peripheral blood lymphocytes and of melanoma cells
from metastases was determined using a standard
microcytotoxicity assay (Dynal, Milan, La Roche,
Switzerland) as described elsewhere.
13
Short-term
melanoma cell cultures were analysed for HLA class
I, HLA class II molecules, intercellular adhesion
molecule-1 (ICAM-1), NCAM and interleukin-12 re-
ceptor using ¯ow cytometry.
13
Between ®ve and 50 atypical melanocytic cells of
the respiratory epithelium, corresponding to the
area of mucosal melanosis, malignant melanoma
tumour cells and normal epidermal cells were
microdissected under light microscope visualization
(magni®cation 3200) using a 30 gauge needle from
two slides for loss of heterozygosity (LOH) analysis.
Procured cells were immediately suspended in 1 g/l
proteinase K, pH 8.0, and incubated for 2 days at
378C. LOH analysis was carried out by PCR ampli®-
cation of microsatellite polymorphisms using two
polymorphic DNA markers at chromosome 9p21,
IFNA and D9S171, which are ¯anking markers of the
p16 gene (Research Genetics, Huntsville, Alabama,
USA), as described elsewhere.
14
Results
Gross and light microscopic features
The primary tumour measured 1.5 cm in diameter
on an area of brown-black pigmented mucosa. The
surface was slightly rugged, glistening and dark
black, with occasional traces of blood. Microscopi-
cally, we found sheets and small nodules of tumour
cells in the lamina propria, with ulceration of the
covering respiratory epithelium. The tumour was
composed of large atypical cells with abundant
cytoplasm, large hyperchromatic nuclei and promi-
nent nucleoli. Brown melanin pigment was present
within the cytoplasm of these cells. Mitotic ®gures
were numerous and some were atypical. Focally, the
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neoplastic pleomorphic cells were more spindle-
shaped. Stains for S-100 protein, tyrosinase, MelanA
and gp100 were strongly positive. Alongside the
malignant melanoma we found areas showing pro-
liferation of atypical melanocytes in the respiratory
epithelium. These cells were strongly immunoposi-
tive for the same markers as the malignant melano-
ma.
In subsequent biopsies of local relapses and meta-
stases, melanoma-associated antigens remained de-
tectable on immunohistochemistry. Increased num-
bers of antigen-speci®c CD8 T cells were isolated
from peripheral blood mononuclear cells following
dendritic cell vaccine (data not shown).
LOH
Microdissected atypical melanocytic cells of the
respiratory epithelium corresponding to the area of
mucosal melanosis showed loss of the lower allele
using the polymorphic marker D9S171, whereas the
malignant melanoma tumour cells showed loss of
both alleles of this ¯anking marker for the p16 gene
(Figure 2). The polymorphic marker IFNA, which is
a ¯anking marker of the p16 gene, was used in the
same PCR reaction and showed homozygosity.
mRNA detection by RT-PCR ELISA
Short-term melanoma cell cultures established from
two lymph node metastases showed mRNA expres-
sion of tyrosinase and MUC18, and no mRNA expres-
sion of MAGE-3 or MelanA/MART-1 (data not
shown). No expression of FasLigand mRNA was
found (data not shown).
HLA status
The HLA status of peripheral blood lymphocytes and
melanoma cells from metastases was determined to
be HLA-A2, -A3, -B7, -B51 using a standard micro-
cytotoxicity assay. No alteration in HLA status was
detected. Short-term melanoma cell cultures from
metastases showed constitutive expression of HLA
class I and II molecules on ¯ow cytometry, which
were upregulated after stimulation with interferon-á
and interferon-ã.
Adhesion molecules and cytokine
receptors
Short-term melanoma cell cultures from metastases
showed constitutive expression of ICAM-1 (CD54),
which was upregulated after interferon stimulation.
No constitutive expression for NCAM (CD56) was
found, but expression was seen after interferon
stimulation.
15
Interleukin-12 receptor was detected
on unstimulated melanoma cells.
16
Discussion
Mucosal melanoma represents only 1.3% of all
reported melanomas and shows a higher incidence
in African-African compared with white non-Hispa-
nic ethnicity.
2
Melanocytes, which can be found in
the nasal cavity,
17
probably develop into melanoma.
Melanosis of the nasal cavity with melanoma is
exceedingly rare, particularly in Caucasians.
4,18
The prognosis of patients with intranasal melano-
ma is poor. Five-year survival rates range from 20 to
60% in historical data; in the most recent study by
Chang et al.
2
the 5-year survival for mucosal
melanoma is 25%, with tumours in the head and
neck region faring slightly better at 31.7%. The
diagnosis is usually established at an advanced stage
of the disease due to the late development of
symptoms, thus delaying treatment.
18
Metastasis can
occur both haematogeneously and lymphatically.
In this study it was possible for the ®rst time to
cultivate melanocytic tumour cells from a nasal
mucosa melanoma. The cells presented no HLA
changes compared with peripheral blood mono-
nuclear cells and reacted with normal HLA class I
Figure 2. Sequence gel analysis results obtained after subjec-
tion of microdissected cells to single-step DNA extraction and
ampli®cation using the primers D9S171 and IFNA (9p21). Loss
of an allele was scored as a . 50% reduction of the band
intensity (arrow). The polymorphic marker IFNA, which was
used in the same PCR reaction, was non-informative (homo-
zygous). N, normal epidermal layer; Ta, mucosal melanosis; Tb,
primary melanoma.
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and II upregulation to interferon-á and -ã stimula-
tion. The cells expressed the melanocytic markers S-
100, gp100, tyrosinase and MelanA on immunohisto-
chemistry. Based on our investigations, the tumour
cells seemed to present no features inhibiting their
recognition by cytotoxic T cells. Therefore dendritic
cell vaccination was undertaken. Continued melano-
ma-associated antigen expression (tyrosinase, Mela-
nA/MART-1, TRP-1 and gp100) on the primary
tumour and metastases was found both in biopsies
and in short-term tumour cell cultures. Dendritic cell
vaccination resulted in an increased frequency of
cytotoxic CD8 lymphocytes recognizing melano-
cytic antigens in the peripheral blood.
Nevertheless, the metastases progressed. Several
mechanisms of tumour escape can be recognized in
this patient. Constitutive expression of ICAM-1
(CD54), as seen in this patient's melanoma cell
cultures, might facilitate tumour escape by the
release of soluble ICAM-1, which interferes with the
attachment of cytotoxic T cells.
19
Increased inter-
leukin-12 receptors on the patient's tumour cells can
mediate interleukin-12-induced upregulation of HLA
class I, HLA class II and ICAM-1 molecules.
16
How-
ever, with HLA class I molecules present on melano-
ma cells, tumour escape could also be due to
de®cient antigen processing machinery or to inter-
leukin-10 secretion by melanoma cells.
20
In the LOH analysis of our patient's melanotic and
tumour cells using the polymorphic marker D9S171,
which is a ¯anking marker for the p16 gene, we
found LOH in the area of melanosis and complete
loss of both alleles within the tumour. Lacking know-
ledge about our patient's nasal mucosa before the
diagnosis of melanoma was made, we have no data
on the chronological order of melanosis and melano-
ma development in this case. The occurrence of LOH
as an early event in tumorigenesis, however, points
to a common origin for both lesions. The repeated
local recurrence of melanoma in the area of melano-
sis supports this concept. The clinical observation of
an increased incidence of mucosal melanosis and
mucosal melanoma in people of African descent is
also suggestive of nasal melanosis as a premalignant
condition.
3
Similar associations have been described
in ocular melanosis, which some authors consider to
be melanoma in situ.
21
Nasal melanosis should there-
fore be closely followed in affected individuals.
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